Estuary Biotherapeutics
- Health & Biotech
- Menlo Park, California, US
- Private
- estuarybio.com
Biotech developing AAV gene therapies for autosomal dominant polycystic kidney disease, with PKD1 and PKD2 programmes.
$103MEquity raised in 2025–20262025 — · 2026 $103M · 2 equity rounds
$103MEquity raised, all time2 equity rounds on record
—Latest valuationnot disclosed
Rounds over time log-scaled amounts
Funding history 2 rounds · 1 source · newest first
- Series AAmount$93MPost-money—✓ Confirmed
- SeedAmount$10MPost-money—✓ Confirmed
Investors 8
- 4BIO Capital2
- GV2
- RA Capital Management1
- Biogen New Ventures
- Deep Track Capital
- National Kidney Foundation Innovation Fund
- Pivotal bioVenture Partners
- UPMC Enterprises
Highlighted investors led at least one equity round; the number is equity rounds taken part in.
Related companies shared investors
Parabilis MedicinesHealth · $975M in 2025–2026Shared: GV, RA Capital ManagementLifeMine TherapeuticsHealth · $263M in 2025–2026Shared: GV, RA Capital ManagementSambaNovaAI Infra · $1.4B in 2025–2026Shared: GVSierraAI Apps · $1.3B in 2025–2026Shared: GVOpenEvidenceHealth · $660M in 2025–2026Shared: GVRecursive SuperintelligenceAI Labs · $650M in 2025–2026Shared: GV
Also in the Menlo Park hub see on the globe
Figures in USD at the time of each round. See the methodology for how rounds are sourced and verified. Estuary Biotherapeutics and its logo are trademarks of their owners, used here for identification only.
